Why the study?
Cerebral thromboembolism is a life-threatening complication after lobectomy for lung cancer, and distinguishing pulmonary vein stump-associated thrombosis from that caused by postoperative atrial fibrillation is challenging.
Does pathological assessment of thrombectomy specimens help determine the etiology and guide treatment for cerebral thromboembolism after lobectomy for lung cancer?
Does pathological assessment of thrombectomy specimens help determine the etiology and guide treatment for cerebral thromboembolism after lobectomy for lung cancer?
Pathological assessment of thrombectomy specimens can help distinguish pulmonary vein stump-associated thrombosis from postoperative atrial fibrillation, guiding appropriate management.
May support etiology distinction in post-lobectomy thromboembolism; hypothesis-generating and requires prospective validation before guiding therapy.
Lung cancer is the leading cause of cancer-related deaths worldwide. Although molecular therapies have emerged as efficacious strategies for the treatment of lung cancer, surgical resection is still recommended as a radical therapeutic option. Currently, lobectomy is regarded as the most reliable radical treatment of primary lung cancer. Among the various complications after lobectomy, cerebral thromboembolism requires attention as a life-threatening complication during the early postoperative period. It occurs in 0.2⁻1.2% of surgical cases of lung cancer and typically develops following left upper lobectomy with a long pulmonary vein stump (PVS). PVS-associated thrombosis is known to cause cerebral thromboembolism after such procedures; however, distinguishing this specific complication from that caused by postoperative atrial fibrillation is challenging. We summarize herein the diagnostic pathology of thrombus formation in accordance with its thrombogenic mechanism. We focus on the potential utility of the pathological assessment of thrombectomy specimens. The morphological information obtained from these specimens enables the presumption of thrombogenic etiology and provides useful clues to both select an appropriate pharmacotherapy and determine a follow-up treatment for cerebral thromboembolism.
No takes yet. Share an insight, caveat, or question.
Hashimoto et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: